- Home
- BAFN vs NBP Comparison
BAFN vs NBP Comparison
Compare BAFN & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BAFN | NBP |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.3M | 205.9M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BAFN | NBP |
|---|---|---|
| Price | $9.05 | $1.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 86.1K | ★ 241.0K |
| Earning Date | 04-30-2026 | 04-07-2026 |
| Dividend Yield | ★ 1.00% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.26 | $1.46 |
| 52 Week High | $11.34 | $5.19 |
Technical Indicators
Market Signals| Indicator | BAFN | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 71.51 | 40.82 |
| Support Level | $5.93 | N/A |
| Resistance Level | N/A | $1.67 |
| Average True Range (ATR) | 0.73 | 0.07 |
| MACD | 0.16 | -0.02 |
| Stochastic Oscillator | 88.42 | 21.67 |
Price Performance
Historical ComparisonAbout BAFN BayFirst Financial Corp.
BayFirst Financial Corp is a bank holding company that operates through its wholly owned subsidiary. The Company generates the majority of its revenue from interest on loans and noninterest income. The primary sources of funding for its loans are loan payments, deposits, and borrowings. It is dependent on noninterest income, which is derived from net gain on the sales of the guaranteed portion of government-guaranteed loans and service fee income. The company provides personal banking and business banking services.
About NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.